AbbVie has struck an immuno-oncology licensing agreement with IGI Therapeutics that is potentially worth more than $1.9 billion to the clinical-stage biotechnology company.

International General Insurance Holdings Ltd. ("IGI" or the "Company") (NASDAQ: IGIC) today announced that it expects to release financial results for the second quarter and half year 2025, on Tuesday ...

US pharma major AbbVie and IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation today ...

IGI has partnered with AbbVie to grant exclusive rights to globally develop, manufacture, and commercialise ISB 2001 across ...

A 23-year-old man has been arrested at the Indira Gandhi International Airport (IGI) here for allegedly impersonating as a Delhi Police sub-inspector by using a forged identity card and fake ...

Glenmark Pharmaceuticals shares rallied 10% on Friday to reach a record high after its biotech subsidiary signed a ...

Glenmark Pharma shares hit upper circuit limit after signing a USD 2 billion deal with AbbVie for a cancer drug. Stock hits ...

Indira Gandhi International Airport (IGIA) in New Delhi has ascended to become the ninth busiest airport globally in 2024, managing over 7.78 crore pa ...

New Delhi: Shares of Glenmark Pharmaceuticals Ltd on Friday jumped 10 per cent after the firm said it has signed a deal with ...

US biopharma company AbbVie has inked a $700 million deal with IGI Therapeutics to develop and sell ISB 2001, an experimental drug for blood cancer.

TV18’s daily newsletter featuring the top 10 stories on markets, corporate updates, economic insights, and financial ...